<?xml version="1.0" encoding="UTF-8"?>
<p>Unlike systemic antibiotics, topical therapies reduce the potential for systemic absorption and side effects (i.e., gastrointestinal), and also lower the potential for developing resistance to life saving systemic antibiotics [
 <xref rid="B11-antibiotics-09-00909" ref-type="bibr">11</xref>,
 <xref rid="B13-antibiotics-09-00909" ref-type="bibr">13</xref>,
 <xref rid="B17-antibiotics-09-00909" ref-type="bibr">17</xref>,
 <xref rid="B46-antibiotics-09-00909" ref-type="bibr">46</xref>]. They are also likely to have better compliance, acceptance, and tolerability than systemic antibiotics due to their shorter treatment courses, and ease of application [
 <xref rid="B20-antibiotics-09-00909" ref-type="bibr">20</xref>,
 <xref rid="B46-antibiotics-09-00909" ref-type="bibr">46</xref>]. They are suitable for direct application to the infection site, and can deliver high drug concentrations to eradicate the bacteria, thereby reducing the potential of antimicrobial resistance [
 <xref rid="B17-antibiotics-09-00909" ref-type="bibr">17</xref>,
 <xref rid="B21-antibiotics-09-00909" ref-type="bibr">21</xref>,
 <xref rid="B49-antibiotics-09-00909" ref-type="bibr">49</xref>]. These characteristics have therefore made topical treatments the most preferred for mild and moderate impetigo [
 <xref rid="B11-antibiotics-09-00909" ref-type="bibr">11</xref>,
 <xref rid="B13-antibiotics-09-00909" ref-type="bibr">13</xref>,
 <xref rid="B17-antibiotics-09-00909" ref-type="bibr">17</xref>,
 <xref rid="B46-antibiotics-09-00909" ref-type="bibr">46</xref>].
</p>
